A Study of a Nucleoside Sparing Regimen in HIV-1 Infected Patients With Detectable Viremia
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Research ipotesis is to assess the efficacy and safety of a nucleos(t)ide sparing regimen of
atazanavir/ritonavir 300 mg /100 mg QD + Dolutegravir 50 mg QD for the management of
virological failure in HIV-1 infected patients.
The Primary Objective is to explore the 24-week efficacy of a nucleos(t)ide sparing regimen
of atazanavir 300 mg QD/ ritonavir 100 mg QD + Dolutegravir 50 mg QD for the management of
virologic failure in HIV-1 infected, integrase inhibitor-naïve subjects.